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Abstract Taxanes are widely used anticancer agents,
produced from the plants of the genus Taxus (yews).
One of the rare side-effects caused by taxanes is a
bilateral cystoid macular oedema (CMO). The partic-
ularity of this type of CMO is that it is angiographically
silent showing no leakage or pooling on fluorescein
angiography (FA). To date, the mechanism of this
oedema has not been clearly understood and existing
theories do not explain this phenomenon very well. Our
aim was to report a case of paclitaxel-induced CMO and
put forward a putative explanation for this occurrence. A
64-year-old woman presented with a 7-month history of
progressively decreasing bilateral visual acuity with an
apparently normal fundus. At entry her best-corrected
visual acuity (BCVA) was 0.4 for far and near OD and
0.5 for far and near OS. Optical coherence tomography
(OCT) revealed a CMO with a central thickness of
561 lm OD and 488 lm OS; there were no signs of
intraocular inflammation. FA showed no capillary
leakage and quasi absent late hyperfluorescence OU.
Indocyanine green angiography was within normal
limits. Classical CMO treatment was ineffective and
only discontinuation of paclitaxel resulted in recovery of
a normal macular structure after 4 weeks with an
increase of BCVA to 0.9 OD and 1.0 OS. In order to
understand the properties of taxane drug-induced cys-
toid macular oedema (TDICMO) we compared the
spectral OCT findings of our case to an inflammation-
induced CMO of equal thickness and to a case of
multifocal choroiditis. The plane of separation of
TDICMO was above the external limiting membrane
in both cases. In contrast to inflammation-induced CMO
where the four external bands were well identified, there
was attenuation of these bands in TDICMO but no
disruption of the layers as seen in multifocal choroiditis,
indicating that the fluid in TDICMO had a high viscosity
producing a shadow underneath. TDICMO most prob-
ably originates from retinal pigment epithelium dys-
function by their effect on microtubule functions and not
from vascular leakage. The content of the CMO seems
to be made up of viscous fluid. As the origin of the CMO
is not inflammatory, classical CMO treatments have no
effect and only discontinuation of the taxane drug allows
reversal of the CMO.
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Introduction
Taxanes [paclitaxel (Taxol), docetaxel (Taxotere),
and protein-bound paclitaxel (Abraxane)] are widely
used anticancer agents produced by the plants of the
genus Taxus (yews) [1, 2]. Their main mechanism of
cytotoxic action is based on the stabilisation of
microtubules leading to cell mitotic inhibition [2, 3].
Since the 1990s, fluid retention is a well-known
adverse effect of the taxane group of drugs [4]. It is
characterised by oedema, weight gain, and third-space
fluid collection (pericardial, pleural, ascites) and appears
to be related to the absolute cumulative dose of taxane
drugs [5]. A significant increase of circulating lympho-
kine-activated killer cells has been reported. Behar et al.
[4] pointed out excessive transcapillary filtration of
proteins. Semb et al. [5] revealed a significant decrease in
colloid osmotic pressure of plasma (COPpl) and inter-
stitial fluid (COPint), haemoglobin, haematocrit, albu-
min, and total protein values, when a cumulative
docetaxel dose reached 200 mg/m2. They suggested that
a plasma volume increase was followed by enhanced
fluid filtration to the interstitium. After a cumulative
docetaxel dose of 500 mg/m2, it was noted that the
COPpl continued to decrease significantly, but COPint
remained unchanged despite a significant increase in
mean body weight and oedema formation [5].
One of the rare side-effects induced by taxanes is a
bilateral visual acuity decrease due to taxane drug-
induced cystoid macular oedema (TDICMO) [6, 7]. To
date, the mechanism of TDICMO has not been clearly
understood. The particularity of TDICMO is that it is
angiographically silent as fluorescein angiography (FA)
fails to show significant capillary leakage and quasi
absent angiographically visible intra- or subretinal
pooling on late frames. Very faint permeability of
retinal vessels has been put forward as an explanation
with a breakdown of the retinal blood–ocular barrier so
minute that even a small fluorescein molecule cannot
extrude or only minimally extrudes [6]. We doubt that
‘microleakage’ is the explanation for TDICMO and
present a new case of paclitaxel-induced CMO and put
forward a pathophysiological explanation.
Case report
A sixty-four-year old female patient presented to the
centre for ophthalmic specialised care (COS) in
Lausanne, Switzerland in December 2010 with a
7-month history of progressively decreasing bilateral
visual acuity and apparently normal fundus findings.
She consulted for a second opinion as no explanation
for the decreased vision could be found.
She had been operated for breast cancer T1 N0 M0 in
2008 and had been receiving adjuvant hormonotherapy.
Since March 30th, 2010, she had received a combination
of Taxol (paclitaxel, cumulative dose 2741.12 mg/m2)
and Avastin (bevacizumab, 20,700 mg), as first-line
chemotherapy for metastatic hormonoresistant disease.
At the beginning of June 2010, 3 months after the
initiation of Taxol therapy she noticed bilateral blurred
vision. Three months later she noticed decreased visual
acuity for which her ophthalmologist had found no
explanation, and finally was seen by us 7 months later.
At entry her best-corrected visual acuity (BCVA)
was 0.4 for far and near OD and 0.5 for far and near
OS. There was no anterior chamber flare OU, and laser
flare photometry showed absence of subclinical
inflammation (5.2 and 5.6 ph/ms, respectively, for
the right and left eyes, i.e., normal values). There was a
slight bilateral cataract and computerised campimetry
showed no significant visual field impairment. Spec-
tral optical coherence tomography (OCT) (Heidelberg
Engineering, Inc., Heidelberg, Germany) showed
bilateral cystoid macular oedema with a central
thickness of 561 lm OD and 488 lm OS with what
appeared as areas of loss of photoreceptor outer
segments but probably corresponded to signal atten-
uation in the areas of maximal oedema (Fig. 1).
FA showed no capillary leakage and very faint
barely visible late fluorescence OU (Fig. 1, middle
pictures). Indocyanine green angiography was within
normal limits showing neither hypofluorescent areas
indicating no hypoperfusion of the choriocapillaris nor
diffuse hyperfluorescence indicating no choroidal
hyperpermeability (Fig. 1, bottom pictures).
Classical treatment for CMO was introduced includ-
ing Diamox (acetazolamide, 250 mg/day), nonsteroidal
drops (indomethacin 0.1 %, 6 9 daily), prednisolone
acetate drops 1 % (Pred Forte, 3 9 daily) with no effect
whatsoever after 5 weeks.
The CMO was then attributed to the Taxol
treatment and we asked her oncologist to discontinue
this treatment. One month later the retinal macular
structure had returned to a normal morphology with a
central thickness of 225 lm OD and 240 lm OS and
normal aspect of the four outer OCT bands (external
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limiting membrane, IS/OS boundary, OS tips, retinal
pigment epithelium [RPE]) (Fig. 2). BCVA returned
to 0.9 OD and 1.0 OS with progression of the bilateral
cataracts. The right cataract was operated 9 months
later and the left cataract was operated 14 months
later. At no time during the surgical follow-up did the
CMO recur even in the immediate post-operative
periods. The oncologist reintroduced a taxane treat-
ment from May 3rd, 2011 until October 18th, 2011
using Taxotere (Docetaxel, cumulative dose
609.14 mg/m2) given together with Xeloda (cape-
citabine) which did not produce recurrence of CMO.
Hypothesis
In order to understand the characteristics of TDICMO,
we compared the spectral OCT findings of our case to
those of an inflammation-induced CMO and to a case
of multifocal choroiditis (MFC) to show the difference
between attenuation of the four outer OCT bands and
their destruction as seen in MFC. The comparison of
these three situations is shown in Fig. 3. Figures 3a
and b are OCT scans of CMOs of equal thicknesses
from our case of TDICMO (3a) and from a case where
CMO is due to inflammation (3b). Figure 3c is from a
case of MFC where the four outer bands are
disorganised and partially destroyed. Separation of
the retina is at the same level, above the external
limiting membrane in both types of oedema. Figure 3a
shows that the four outer bands are present in
TDICMO unlike Fig. 3c, from a case of MFC, where
they are segmentally destroyed and/or disorganised. It
can also be noted that the appearance of the four outer
bands are attenuated in the areas of maximal oedema,
possibly indicating high-viscosity fluid present in
TDICMO. Figure 3b shows an inflammation-induced
CMO; the structure of the four outer bands is clearly
visible without attenuation and comparable to a
normal scan (Fig. 3d), probably indicating a less
viscous fluid that is not producing a shadow. Conse-
quently it is thought that the density of the CMO fluid
Fig. 1 Bilateral cystoid
macular oedema with a
central thickness of 561 lm
OD and 488 lm OS. FA
shows no capillary leakage
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caused by paclitaxel is higher than the inflammation-
induced CMO, as it produces a masking effect on
intact outer bands.
Figure 3c illustrates segmental destruction and/or
disorganisation of the four outer bands in a case of
MFC which contrasts with the preserved but attenu-
ated outer bands of TDICMO. Taking into account the
location of the oedema in the outer retinal layers, the
cause of the oedema should be sought in the dysfunc-
tion of the RPE [8, 9].
Discussion
Macular oedema or cystoid macular oedema (CMO) is
a common cause of vision impairment and is classi-
cally demonstrated by FA, showing capillary leakage
followed by pooling. CMO without fluorescein leak-
age is a rare occurrence. Only a few conditions are
associated with angiographically silent CMO, and
these include some types of retinitis pigmentosa,
juvenile X-linked retinoschisis, Goldmann-Favre syn-
drome and niacin toxicity [10]. The pathogenesis of
angiographically silent TDICMO is still unclear but
resembles niacin-induced CMO. Several authors
explained niacin-induced CMO, which is comparable
to TDICMO, as a result of accumulation of intracel-
lular fluid and suggested dysfunction of intracellular
metabolism as a leading cause [11, 12].
Investigations performed in our case as well as its
clinical evolution give us some sound elements that
allow us to put forward a putative but meaningful
hypothesis for the occurrence of angiographically
silent macular oedema such as TDICMO.
It is clear that the mechanism is not inflammatory.
Absence of both fluorescein leakage as well as late
hyperfluorescence indicate that there is no inflamma-
tory capillary leakage to explain the presence of
subretinal fluid. In support of this are several addi-
tional observations: (1) there were no vitreous cells to
be seen, (2) there was no subclinical inflammation
detected by laser flare photometry which always
showed normal values, (3) anti-inflammatory treat-
ment associating steroid and non-steroidal drops had
no effect whatsoever on the oedema, and (4) nine and
14 months after the resolution of the bilateral oedemas
the right and left cataract were operated, respectively,
which failed to produce neither CMO nor OCT
thickening of the maculas, showing that the patient’s
maculas were not prone to develop inflammatory
oedema.
The mechanism of TDICMO probably differs from
the one of fluid retention syndrome in other parts of the
body. In the literature it is known that docetaxel is
more likely to be associated with a fluid retention
syndrome than paclitaxel as in our case, which can be
dose-limiting [13]. The cumulative dose of docetaxel
needed for this side-effect is 300–400 mg/m2 and it
was increased with additional treatment of corticoste-
roids to 746 mg/m2 [4].
OCT images show that the plane of separation of
the oedema is above the four outer bands. The origin of
this type of oedema has to be sought at the level of the
RPE. One explanation for the angiographic silence is
Fig. 2 Top pictures shows bilateral CMO after 10 months of Taxol treatment; bottom pictures show normal maculas 4 weeks after
discontinuation of Taxol therapy
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that the origin of the fluid is not from retinal vessels
but is probably due to a malfunctioning RPE. Taxol
was shown to disturb the microtubule structure in
RPE cells, preventing microtubule disassembly,
consequently blocking many microtubule-dependent
processes in the RPE [14]. This cytoskeleton-disrupt-
ing effect possibly impairs microtubule-dependent
transport directed from the apical part of the cell
Fig. 3 Difference of the
four outer bands in a CMO
due to Taxol showing
attenuation of these bands
(arrow), b CMO due to
inflammation where the four
outer bands are well visible
(arrow), c MFC showing
segmental destruction of the
four outer bands (arrow),
and d a normal retinal
structure (arrow)
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towards the base of the RPE cell, possibly allowing
proteins to accumulate under the retina and/or dis-
turbing fluid absorption across the RPE [15].
The fluid is not coming directly from the choroid by
disruption of tight junctions between RPE cells as
there is no leaking point visible neither on FA nor on
indocyanine green angiography as seen for example in
central serous chorioretinopathy (CSC). Furthermore,
no hyperpermeability of choroidal vessels is seen on
ICGA as in CSC. The suspected cellular origin of the
fluid also explains why none of the circulating
fluorescein is getting into these spaces. The suspected
elevated viscosity of the exudates could also be an
obstacle to diffusion of fluorescein representing an
additional reason for the absence of hyperfluores-
cence. OCT images indicate that the density of the
fluid in the oedema is rather high as it constitutes a
shadow for the four outer bands in contrast to the fluid
in inflammatory-induced CMO where there is no
attenuation of this layer. TDICMO is comparable to
oedema in X-linked retinoschisis, which is also
angiographically silent, and TDICMO can be consid-
ered the reversible counterpart of non-reversible
hereditary dysfunction of the RPE. Further evidence
for the suggested pathophysiological mechanism is
that the only effective treatment is discontinuation of
taxoid medication.
One remaining question is why one taxane drug,
Taxol (paclitaxel) was toxic to the RPE while another
compound Taxotere (docetaxel) was not. Possibly a
certain amount of cumulative dose is necessary to
induce the TDICMO and this was not reached by the
second compound. In other systemic situations of fluid
retention syndrome, the cumulative dose needed to
cause side-effects was 300–400 mg/m2 for Taxotere
without corticosteroid treatment and rises to 746 mg/
m2 with corticosteroid therapy. Although all three types
of taxanes have been shown to be able to induce
TDICMO, it is also possible that some patients are at
risk for CMO when taking one taxane, but are not prone
to develop CMO with another taxane. Further studies
are necessary to solve the mystery of angiographically
silent macular oedema.
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